Director Karen J. Wilson boosts Serina (SER) stake with 10,100-share purchase

Rhea-AI Filing Summary

Serina Therapeutics director Karen J. Wilson bought additional common stock in two recent open-market purchases. She acquired 5,100 shares on June 11, 2026 at a weighted average price of $1.745 per share and 5,000 shares on June 12, 2026 at a weighted average price of $1.77 per share. After these transactions, she directly owns 10,100 shares of Serina Therapeutics common stock. The filing notes that each day’s price reflects multiple trades within narrow ranges around the reported averages.

Insider Trade Summary

Net Buyer: 10,100 shares ($17,750)

Net Buy 2 txns

Insider WILSON KAREN J

Role null

Bought 10,100 shs ($18K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$1.77	$9K
Purchase	Common Stock	5,100	$1.745	$9K

Holdings After Transaction: Common Stock — 10,100 shares (Direct, null)

Footnotes (1)

1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.745 per share to a high purchase price of $1.75 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.77 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Key Figures

Shares bought June 11, 2026: 5,100 shares Shares bought June 12, 2026: 5,000 shares Total shares bought in filing: 10,100 shares +3 more

6 metrics

Shares bought June 11, 2026 5,100 shares Open-market purchase at weighted average $1.745 per share

Shares bought June 12, 2026 5,000 shares Open-market purchase at weighted average $1.77 per share

Total shares bought in filing 10,100 shares Net buy shares across two transactions

Holdings after transactions 10,100 shares Total direct common stock owned following June 12, 2026 trade

Price range June 11, 2026 $1.745–$1.75 per share Weighted average purchase price based on multiple trades

Price range June 12, 2026 $1.76–$1.77 per share Weighted average purchase price based on multiple trades

Key Terms

open-market purchase, weighted average purchase price, reporting person, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for both common stock transactions"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reflects the weighted average purchase price of multiple transactions"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

reporting person regulatory

"the reporting person agrees to provide the number of shares"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): details the insider’s transactions"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON KAREN J

(Last) (First) (Middle)

601 GENOME WAY

SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		P		5,100	A	$1.745	5,100(1)	D
Common Stock	06/12/2026		P		5,000	A	$1.77	10,100(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.745 per share to a high purchase price of $1.75 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

2. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.77 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Remarks:

	/s/ Karen J. Wilson	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Serina Therapeutics (SER) disclose?

Serina Therapeutics disclosed that director Karen J. Wilson bought common stock in two open-market transactions, totaling 10,100 shares. These purchases occurred on June 11 and June 12, 2026, at weighted average prices around the mid-$1.70s per share.

How many Serina Therapeutics (SER) shares did Karen J. Wilson buy?

Karen J. Wilson bought a total of 10,100 Serina Therapeutics common shares. She purchased 5,100 shares on June 11, 2026 and 5,000 shares on June 12, 2026, increasing her direct holdings to 10,100 shares after the transactions.

At what prices were the recent Serina Therapeutics (SER) insider purchases made?

The reported weighted average prices were $1.745 per share on June 11, 2026 and $1.77 per share on June 12, 2026. Footnotes state each average reflects multiple trades in narrow ranges around those prices on the respective dates.

Who is the insider involved in the latest Serina Therapeutics (SER) Form 4?

The insider is Karen J. Wilson, a director of Serina Therapeutics. She reported two open-market purchases of common stock, resulting in direct ownership of 10,100 shares following the transactions disclosed in the Form 4.

Does Karen J. Wilson hold Serina Therapeutics (SER) shares directly or indirectly?

According to the Form 4, Karen J. Wilson’s reported holdings are classified as direct ownership. After the June 11 and June 12, 2026 open-market purchases, her direct position in Serina Therapeutics common stock stands at 10,100 shares.